Cargando…

Intensified treatment of hyperphosphatemia associated with reduction in parathyroid hormone in patients on maintenance hemodialysis

Background: This study investigated the therapeutic effect of intensive phosphorus-lowering therapy on intact-parathyroid hormone (iPTH) levels in hemodialysis patients. Methods: Ninety-five hemodialysis patients with serum phosphorus ≥1.78 mmol/L and iPTH ≥300 pg/dL were apportioned to either the t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Lan, He, Jin-Xuan, Chen, Ying-Ying, Ling, Yi-Sheng, Lin, Chun-Hua, Guan, Tian-Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2018
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6014480/ https://www.ncbi.nlm.nih.gov/pubmed/29295646 http://dx.doi.org/10.1080/0886022X.2017.1419966

Ejemplares similares

Investigation of optimum N-terminal probrain natriuretic peptide level in patients on maintained hemodialysis
por: Chen, Lan, et al.
Publicado: (2017)

Effects of three blood purification methods on serum fibroblast growth factor-23 clearance in patients with hyperphosphatemia undergoing maintenance hemodialysis
por: MIAO, LI-YING, et al.
Publicado: (2014)

Parathyroid Hormone Concentrations in Maintenance Hemodialysis: Longitudinal Evaluation of Intact and Biointact Assays
por: Berner, Carolin, et al.
Publicado: (2021)

Control of hyperphosphatemia and maintenance of calcemia in CKD
por: Carvalho, Aluizio Barbosa, et al.
Publicado: (2021)

Safety and efficacy of nicotinamide in the management of hyperphosphatemia in patients on hemodialysis
por: Vasantha, J., et al.
Publicado: (2011)

NaPi-IIb Inhibition for Hyperphosphatemia in CKD Hemodialysis Patients
por: Maruyama, Sonomi, et al.
Publicado: (2020)

The optimal range of serum intact parathyroid hormone for a lower risk of mortality in the incident hemodialysis patients
por: Zhou, Xiaoling, et al.
Publicado: (2021)

Effect of low-dose lanthanum carbonate on calcium and phosphorus metabolism in Asian Patients with end-stage renal disease, maintenance hemodialysis and hyperphosphatemia
por: Cui, Xiaofei, et al.
Publicado: (2022)

Hyperphosphatemia is associated with patency loss of arteriovenous fistula after 1 year of hemodialysis
por: Moon, Ju-Young, et al.
Publicado: (2015)

Infective spondylodiscitis in patients on maintenance hemodialysis: a case series
por: Lu, Yueh-An, et al.
Publicado: (2016)

Relationship between parathyroid mass and parathyroid hormone level in hemodialysis patients with secondary hyperparathyroidism
por: Fang, Li, et al.
Publicado: (2015)

Sevelamer carbonate in the treatment of hyperphosphatemia in patients with chronic kidney disease on hemodialysis
por: Savica, Vincenzo, et al.
Publicado: (2008)

Meta-analysis of the efficacy and safety of sevelamer as hyperphosphatemia therapy for hemodialysis patients
por: Zeng, Qian, et al.
Publicado: (2023)

Analysis of the parathyroid function in maintenance hemodialysis patients from Changchun, China
por: Du, Juan, et al.
Publicado: (2017)

Association between Circulating Endothelial Cells and Carotid Atherosclerosis in Patients Receiving Maintenance Hemodialysis
por: Kun-ying, Zhang, et al.
Publicado: (2014)

Intact parathyroid hormone and whole parathyroid hormone assay results disagree in hemodialysis patients under cinacalcet hydrochloride therapy
por: Koda, Ryo, et al.
Publicado: (2014)

Hyperphosphatemia is associated with high mortality in severe burns
por: Kuo, George, et al.
Publicado: (2018)

Low calcium dialysate combined with CaCO(3) in hyperphosphatemia in hemodialysis patients
por: GAO, ZHUO, et al.
Publicado: (2013)

Calcium Acetate or Calcium Carbonate for Hyperphosphatemia of Hemodialysis Patients: A Meta-Analysis
por: Wang, Yong, et al.
Publicado: (2015)

Efficacy of crushed lanthanum carbonate for hyperphosphatemia in hemodialysis patients undergoing tube feeding
por: Kitajima, Yukie, et al.
Publicado: (2011)

Hyperphosphatemia is not significantly associated with increased all-cause mortality in Korean hemodialysis patients
por: Wakasugi, Minako, et al.
Publicado: (2018)

Relationship between the triglyceride–glucose index and coronary artery calcification in asymptomatic, non-diabetic patients undergoing maintenance hemodialysis
por: Ding, Hong, et al.
Publicado: (2023)

Parathyroid Hormone Reduction Predicts Transient Hypocalcemia after Total Thyroidectomy: A Single-Center Prospective Study
por: Mo, Kangnan, et al.
Publicado: (2020)

The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia
por: Block, Geoffrey A, et al.
Publicado: (2019)

Angiotensin-Converting Enzyme Inhibition and Parathyroid Hormone Secretion
por: Zaheer, Sarah, et al.
Publicado: (2017)

Parathyroid hormone-producing cells exist in adipose tissues surrounding the parathyroid glands in hemodialysis patients with secondary hyperparathyroidism
por: Kakuta, Takatoshi, et al.
Publicado: (2020)

Hyperphosphatemia and Cardiovascular Disease
por: Zhou, Chao, et al.
Publicado: (2021)

Factors associated with subgroups of fatigue in maintenance hemodialysis patients: a cross-sectional study
por: Zheng, Xiao-Yan, et al.
Publicado: (2023)

The role of lung ultrasonography in the assessment of overhydration in maintenance hemodialysis patients
por: Cui, Linlin, et al.
Publicado: (2023)

Bone responsiveness to parathyroid hormone is negatively associated with parathyroid hormone-lowering drug use in patients undergoing hemodialysis: a cross-sectional study
por: Tominaga, Naoto, et al.
Publicado: (2021)

Association between the risk of death and serum calcium, phosphate, and intact parathyroid hormone levels in older patients undergoing maintenance hemodialysis: a cohort study in Beijing
por: Li, Dishan, et al.
Publicado: (2021)

The impact of gingivitis reduction on lung function: a randomized trial under intensified oral hygiene
por: Kühnisch, Jan, et al.
Publicado: (2023)

Hyperphosphatemia and its relationship with blood pressure, vasoconstriction, and endothelial cell dysfunction in hypertensive hemodialysis patients
por: Jung, Jinwoo, et al.
Publicado: (2022)

High Dose ESAs Are Associated with High iPTH Levels in Hemodialysis Patients with End-Stage Kidney Disease: A Retrospective Analysis
por: Chen, Lan, et al.
Publicado: (2015)

The triglyceride-glucose index as a novel marker associated with sarcopenia in non-diabetic patients on maintenance hemodialysis
por: Chen, Ruoxin, et al.
Publicado: (2022)

Efficacy comparison of atorvastatin versus rosuvastatin on blood lipid and microinflammatory state in maintenance hemodialysis patients
por: Tian, Jianwei, et al.
Publicado: (2016)

Tenapanor Improves Long-Term Control of Hyperphosphatemia in Patients Receiving Maintenance Dialysis: the NORMALIZE Study
por: Silva, Arnold L., et al.
Publicado: (2023)

Incidence of bone fractures among patients on maintenance hemodialysis
por: Kashgary, Abdullah, et al.
Publicado: (2023)

Hemodialysis patients with low serum parathyroid hormone levels have a poorer prognosis than those with secondary hyperparathyroidism
por: Yu, Yue, et al.
Publicado: (2020)

Magnesium Modifies the Cardiovascular Mortality Risk Associated with Hyperphosphatemia in Patients Undergoing Hemodialysis: A Cohort Study
por: Sakaguchi, Yusuke, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_8fv89bvnedgs05be1iegbufs4r